MED12 overexpression is a frequent event in castration-resistant prostate cancer.
Adler D, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.
Adler D, et al. Among authors: kirfel j.
Endocr Relat Cancer. 2014 Aug;21(4):663-675. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.
Endocr Relat Cancer. 2014.
PMID: 24938407